Unknown

Dataset Information

Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes.


ABSTRACT: Association of single nucleotide polymorphisms in the IL-23 receptor with several auto-inflammatory diseases, led to the heterodimeric receptor and its cytokine-ligand IL-23, becoming important drug targets. Successful antibody-based therapies directed against the cytokine have been licenced and a class of small peptide antagonists of the receptor have entered clinical trials. These peptide antagonists may offer therapeutic advantages over existing anti-IL-23 therapies, but little is known about their molecular pharmacology. In this study, we use a fluorescent version of IL-23 to characterise antagonists of the full-length receptor expressed by living cells using a NanoBRET competition assay. We then develop a cyclic peptide fluorescent probe, specific to the IL23p19:IL23R interface and us

SUBMITTER: Lay CS 

PROVIDER: S-EPMC10199020 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature